Borouge, Mubadala Bio join forces to boost UAE’s healthcare manufacturing

Abu Dhabi: Borouge, a leading petrochemicals company, has signed a strategic agreement with Mubadala Bio to advance local production of medical-grade materials in the UAE, as part of the country’s push to strengthen its healthcare and life sciences sectors.

The partnership was formalised at the ongoing Make it in the Emirates forum and aims to reinforce the UAE’s domestic manufacturing capabilities and reduce reliance on imported healthcare products. The agreement supports the national Operation 300 Billion strategy and aligns with the Make it in the Emirates industrial growth agenda.

Borouge will supply Mubadala Bio with polyolefins tailored for medical use, starting with Bormed™ RG868MO, the UAE’s first locally produced polyolefin designed for healthcare applications. Already in production at Borouge’s Al Ruwais facility, the material meets sterilisation and mechanical standards required for syringes, inhalers, and pharmaceutical packaging.

Mubadala Bio, launched this week, consolidates biopharma and pharma logistics capabilities under one platform, aiming to supply over 100 countries through 10 facilities worldwide, six of which are based in the UAE. With a manufacturing capacity of 2.5 billion tablets and 120 million injectables annually, the new entity is expected to significantly improve local drug security and access to affordable treatments.

Executives from both firms said the partnership reflects their shared commitment to innovation, sustainability, and national self-reliance in healthcare.